Drug interactions with statins

被引：34

作者：

Causevic-Ramosevac, Anida ^{[1
]}

Semiz, Sabina ^{[2
,3
]}

机构：

[1] Joint Stock Co, Bosnalijek, Pharmaceut & Chem Ind, Sarajevo, Bosnia & Herceg

[2] Univ Sarajevo, Fac Pharm, Sarajevo 71000, Bosnia & Herceg

[3] Int Univ Sarajevo, Fac Engn & Nat Sci, Sarajevo, Bosnia & Herceg

来源：

ACTA PHARMACEUTICA | 2013年 / 63卷 / 03期

关键词：

statins; drug interactions; cytochrome P450 (CYP) enzymes; drug transporters; adverse effects; PLASMA PRAVASTATIN CONCENTRATIONS; HIV-SERONEGATIVE VOLUNTEERS; RENAL-FAILURE SECONDARY; GRAPEFRUIT JUICE; SIMVASTATIN ACID; IN-VITRO; REDUCTASE INHIBITORS; CONCOMITANT USE; CONCURRENT USE; PHARMACOKINETIC INTERACTIONS;

D O I：

10.2478/acph-2013-0022

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally well tolerated as monotherapy. Statins are associated with two important adverse effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is most likely to occur when statins are administered with other drugs. Statins are substrates of multiple drug transporters (including OAT-P1B1, BCRP and MDR1) and several cytochrome P450 (CYP) enzymes (including CYP3A4, CYP2C8, CYP2C19, and CYP2C9). Possible adverse effects of statins can occur due to interactions in concomitant use of drugs that substantially inhibit or induce their methabolic pathway. This review summarizes the most important interactions of statins.

引用

页码：277 / 293

页数：17

共 132 条

[1] Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG study A5108 [J].

Aberg, JA ;

Rosenkranz, SL ;

Fichtenbaum, CJ ;

Alston, BL ;

Brobst, SW ;

Segal, Y ;

Gerber, JG .

AIDS, 2006, 20 (05) :725-729

[2] LOVASTATIN - WARFARIN INTERACTION [J].

AHMAD, S .

ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (11) :2407-2407

[3]

Akram K., 2007, INT J CARDIOL, V118, P19

[4]

Alsheikh-Ali Alawi A, 2005, Prev Cardiol, V8, P95, DOI 10.1111/j.1520-037X.2005.4060.x

[5] MACROLIDES VERSUS AZALIDES - A DRUG-INTERACTION UPDATE [J].

AMSDEN, GW .

ANNALS OF PHARMACOTHERAPY, 1995, 29 (09) :906-917

[6] A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers [J].

Amsden, GW ;

Kuye, O ;

Wei, GCG .

JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (04) :444-449

[7] Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin [J].

Ando, H ;

Tsuruoka, S ;

Yanagihara, H ;

Sugimoto, K ;

Miyata, M ;

Yamazoe, Y ;

Takamura, T ;

Kaneko, S ;

Fujimura, A .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (05) :494-497

[8] The interaction of diltiazem with lovastatin and pravastatin [J].

Azie, NE ;

Brater, DC ;

Becker, PA ;

Jones, DR ;

Hall, SD .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) :369-377

[9] Plasma concentrations of active simvastatin acid are increased by gemfibrozil [J].

Backman, JT ;

Kyrklund, C ;

Kivistö, KT ;

Wang, JS ;

Neuvonen, PJ .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :122-129

[10] Ongoing Challenges in Drug Interaction Safety: from Exposure to Pharmacogenomics [J].

Bai, Jane P. F. .

DRUG METABOLISM AND PHARMACOKINETICS, 2010, 25 (01) :62-71

← 1 2 3 4 5 6 7 8 9 10 →